Seagen Inc (SGEN) - Financial and Strategic SWOT Analysis Review

February 2021 | 59 pages | ID: S1D58F31C34EN
GlobalData

Abstracts

Seagen Inc (SGEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Seagen Inc (Seagen), formerly Seattle Genetics Inc, is a biotechnology company that discovers, develops and markets monoclonal antibody-based therapies for the treatment of cancer. It markets antibody-drug conjugates (ADCs) including Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma, T-cell lymphomas, and CD30-expressing lymphomas; and Padcevtm (enfortumab vedotin-ejfv) to treat metastatic urothelial cancers. The company’s pipeline consists of novel therapies that for addressing the unmet medical needs of blood-related cancers and solid tumors. Seagen products and pipeline are based on ADC technology that targets monoclonal antibodies and delivers agents for killing cancer cells. The company sells its products through specialty distributors. Seagen is headquartered in Bothell, Washington, the US.

Seagen Inc Key Recent Developments

Feb 24,2021: Seagen to Present at the Cowen 41st Annual Healthcare Conference
Feb 11,2021: Seagen Reports Fourth Quarter and Full Year 2020 Financial Results
Nov 09,2020: Seagen Highlights immuno-oncology data from broad portfolio during SITC Virtual Annual Meeting 2020
Oct 29,2020: Seagen reports third quarter 2020 financial results
Oct 08,2020: Seattle Genetics announces corporate name change to Seagen

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

Table of Contents
List of Tables
List of Figures

SECTION 1 - ABOUT THE COMPANY

Seagen Inc - Key Facts
Seagen Inc - Key Employees
Seagen Inc - Key Employee Biographies
Seagen Inc - Major Products and Services
Seagen Inc - History
Seagen Inc - Company Statement
Seagen Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Seagen Inc - Business Description
Business Segment: Collaboration and License Agreement Revenue
Performance
Business Segment: Net Product Sales
Performance
Business Segment: Royalty Revenues
Performance
R&D Overview
Seagen Inc - Corporate Strategy
Seagen Inc - SWOT Analysis
SWOT Analysis - Overview
Seagen Inc - Strengths
Seagen Inc - Weaknesses
Seagen Inc - Opportunities
Seagen Inc - Threats
Seagen Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Seagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Seagen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Seagen Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 24, 2021: Seagen to Present at the Cowen 41st Annual Healthcare Conference
Feb 11, 2021: Seagen Reports Fourth Quarter and Full Year 2020 Financial Results
Nov 09, 2020: Seagen highlights immuno-oncology data from broad portfolio during SITC Virtual Annual Meeting 2020
Oct 29, 2020: Seagen reports third quarter 2020 financial results
Oct 08, 2020: Seattle Genetics announces corporate name change to Seagen
Aug 27, 2020: Seattle Genetics highlights data from broad oncology portfolio during ESMO Virtual Congress 2020
Aug 18, 2020: Seattle Genetics appoints Ted W. Love, M.D., to Board of Directors
Jul 30, 2020: Seattle Genetics reports second quarter 2020 financial results
May 13, 2020: Seattle Genetics highlights data from expanding oncology portfolio during virtual scientific program of the 2020 ASCO annual meeting
Apr 30, 2020: Seattle Genetics reports first quarter 2020 financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Seagen Inc, Key Facts
Seagen Inc, Key Employees
Seagen Inc, Key Employee Biographies
Seagen Inc, Major Products and Services
Seagen Inc, History
Seagen Inc, Subsidiaries
Seagen Inc, Key Competitors
Seagen Inc, Ratios based on current share price
Seagen Inc, Annual Ratios
Seagen Inc, Annual Ratios (Cont...1)
Seagen Inc, Interim Ratios
Seagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Seagen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Seagen Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Seagen Inc, Performance Chart (2016 - 2020)
Seagen Inc, Ratio Charts
Seagen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Seagen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

COMPANIES MENTIONED

Xencor Inc
Teva Pharmaceuticals USA Inc
Spectrum Pharmaceuticals Inc
Sanofi AB
Pfizer AG
Novartis AG
ImmunoGen Inc
Dare Bioscience Inc
Cellectar Biosciences Inc
Celgene Corp
Bristol-Myers Squibb Co
Amgen Inc